3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
pembrolizumab
30
Paclitaxel
12
Carboplatin
10
Cisplatin
8
lenvatinib
7
Pemetrexed
5
belzutifan
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Capecitabine
4
patritumab deruxtecan
3
olaparib
3
Leucovorin
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
enfortumab vedotin
×
30 days
×
Clear all
No trials found.